MGC Pharma is set to receive a grant of €3.1 million from the Maltese Government to help fund the manufacture of its ArtemiC COVID-19 anti-inflammatory treatment on the island.
The money, from economic development agency Malta Enterprise, will be used to renovate and extend the company’s existing Clinical Research Organisation (CRO) facility in Malta to include a fully functioning GMP-certified manufacturing facility for liquid dose form and ArtemiC.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.